Skip to main content
logo
Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.900
+0.220 (4.70%)
At close: Feb 24, 2026, 4:00 PM EST
4.900
0.00 (0.00%)
Pre-market: Feb 25, 2026, 7:00 AM EST

Coya Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
3.993.556---
Revenue Growth (YoY)
-58.26%-40.79%----
Cost of Revenue
13.7311.875.54.41--
Gross Profit
-9.74-8.310.5-4.41--
Selling, General & Admin
10.328.897.834.852.310.67
Research & Development
----2.540.04
Operating Expenses
10.348.917.864.874.870.7
Operating Income
-20.09-17.22-7.36-9.29-4.87-0.7
Interest Expense
------0.06
Interest & Investment Income
1.451.650.64---
Other Non Operating Income (Expenses)
----2.43-0.020
EBT Excluding Unusual Items
-18.64-15.58-6.72-11.72-4.89-0.76
Pretax Income
-19.15-15.6-7.26-12.24-4.89-1.1
Income Tax Expense
-0.72-0.720.72---
Net Income
-18.43-14.88-7.99-12.24-4.89-1.1
Net Income to Common
-18.43-14.88-7.99-12.24-4.89-1.1
Shares Outstanding (Basic)
171510332
Shares Outstanding (Diluted)
171510332
Shares Change (YoY)
19.60%49.93%292.40%0.01%40.88%-
EPS (Basic)
-1.11-0.98-0.79-4.73-1.89-0.60
EPS (Diluted)
-1.11-0.98-0.79-4.73-1.89-0.60
Free Cash Flow
-12.14-10.29-11.19-7.24-4.04-0.59
Free Cash Flow Per Share
-0.73-0.68-1.10-2.79-1.56-0.32
Gross Margin
-244.35%-233.86%8.34%---
Operating Margin
-503.76%-484.65%-122.62%---
Profit Margin
-462.25%-418.70%-133.08%---
Free Cash Flow Margin
-304.48%-289.50%-186.41%---
EBITDA
-20.06-17.2-7.33-9.26-4.85-
EBITDA Margin
---122.17%---
D&A For EBITDA
0.030.030.030.030.02-
EBIT
-20.09-17.22-7.36-9.29-4.87-0.7
EBIT Margin
---122.62%---
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q